Taken together, these data are consistent with the hypothesis that increased plasma levels of APOC3 predispose animals to NAFLD and hepatic insulin resistance, which in turn can be attributed to DAG-induced PKCε activation resulting in decreased insulin signaling. Here, APOC3 is linked to metabolic dysfunction-associated steatotic liver disease.